News Breaks |
|
|
| March 20, 2013 |
| 07:19 EDT |  | TEVA | Teva's Azilect for Parkinson's disease shows positive results in study
Teva and H. Lundbeck A/S announced that a double-blind, placebo controlled, randomized, multicenter study of Azilect (rasagiline tablets) met its primary endpoint. The study assessed the efficacy and tolerability of Azilect as add-on treatment to dopamine agonists compared to placebo. Results from the study demonstrated that the addition of Azilect 1mg/day provided a statistically significant improvement in total Unified Parkinson’s Disease Rating Scale score from baseline to week 18 in patients sub-optimally controlled with dopamine agonist monotherapy compared to placebo. Azilect was well-tolerated with no significant difference in adverse events compared to placebo. |
|
|
News For TEVA From The Last 14 Days Check below for free stories on TEVA the last two weeks. |
|
|
| May 13, 2013 |
| 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
 Subscribe for More Information |
|
| 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| May 10, 2013 |
| 10:00 EDT |  | TEVA | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| May 9, 2013 |
| 16:35 EDT | | TEVA | Teva initiated with an Outperform at BMO Capital
Subscribe for More Information |
|
| May 8, 2013 |
| 12:03 EDT | | TEVA | Teva says data demonstrates ovulatory effect of investigational contraceptive
Subscribe for More Information |
|
| 10:26 EDT | | TEVA | Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
Subscribe for More Information |
|
| 09:06 EDT |  | TEVA | Alexza Pharmaceuticals to host conference call
Subscribe for More Information |
|
| 08:33 EDT | | TEVA | Teva, Alexza announce Teva's license to market Adasuve in the U.S.
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. |
|
| May 7, 2013 |
| 11:50 EDT | | TEVA | Teva rival receives patent for once a month Copaxone
Subscribe for More Information |
|
| May 6, 2013 |
| 07:18 EDT | | TEVA | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
| |
|
|
|
|
